International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

So, AstraZeneca's revenue reached $13.59 billion ... camizestrant, rilvegostomig, and tozorakimab, its EBIT margin reached 27.7% in Q1 2025, up about 3.4% year-over-year. I'll continue with ...

AstraZeneca wrapped up the phase 2b, which administered tozorakimab in combination with its kidney disease drug Farxiga, last year and began analyzing whether the investigational molecule improved ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 ...

Tozorakimab (MEDI3506, AstraZeneca) is an anti-IL-33 monoclonal antibody, according to the poster. “The FRONTIER-4 study results show encouraging clinical efficacy signals for tozorakimab as a ...

AstraZeneca (NASDAQ:AZN ... including camizestrant, baxdrostat, tozorakimab, and eneboparatide. At the same time, when forecasting the growth rates of the company's revenue and operating income ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...